Help start a  movement for  more patients

More Options, More Access, More Choice for your patients with arthritic conditions

About TOFIDENCE

Find out more
About Tofidence
About Tofidence

Information about TOFIDENCE, Indications, and Administration

Clinical Trials

Find out more
Clinical Trials
Clinical Trials

How does TOFIDENCE compare to reference tocilizumab?

Our Commitment

Find out more
Our Commitment
Our Commitment

Our commitment to immunology biosimilars and healthcare sustainability

About TOFIDENCE

  • TOFIDENCE is a tocilizumab biosimilar indicated for use in patients with1*:
    • Rheumatoid arthritis (RA)
    • Polyarticular juvenile idiopathic arthritis (pJIA)
    • Systemic juvenile idiopathic arthritis (sJIA)
    • COVID-19
  • Equivalent efficacy and comparable safety profile to reference tocilizumab2
  • A cost-effective treatment option

* Please refer to the full prescribing information or Summary of Product Characteristics for further details

How does TOFIDENCE work?3

Adapted from: Fu B, et al. 2020.

receptor il mediator
receptor il mediator

lL-6

gp130

lL-6
Receptor

glycoprotein glycoprotein glycoprotein glycoprotein glycoprotein glycoprotein glycoprotein glycoprotein membrane receptor membrane receptor membrane receptor membrane receptor molecule of tocilizumab

tocilizumab

molecule of tocilizumab
receptor molecule of tocilizumab
receptor molecule of tocilizumab
il mediator il mediator il mediator il mediator arrow arrow arrow arrow x-mark x-mark

SIGNAL TRANSDUCTION

INFLAMMATORY RESPONSE

REDUCED IL-6 SIGNAL TRANSDUCTION

REDUCED INFLAMMATION

Adapted from: Fu B, et al. 2020.

Targets the inflammatory cytokine IL‑6, a protein which has been linked to RA and other arthritic conditions when its production is dysregulated1

Binds to membrane-bound and soluble forms of the IL‑6 receptor to inhibit IL‑6 signaling, which results in a reduction of inflammatory activity1

Multiple clinical trials have demonstrated the efficacy of reference tocilizumab as monotherapy or in combination with DMARDs for adult patients with moderate-to-severe RA and pediatric patients with pJIA or active sJIA1,4‑11

Abbreviations: COVID-19, Coronavirus disease 2019; DMARD, disease modifying anti-rheumatic drug; gp130, glycoprotein 130; IL-6, interleukin 6; pJIA, polyarticular juvenile idiopathic arthritis; RA, rheumatoid arthritis; sJIA, systemic juvenile idiopathic arthritis.